Rani Therapeutics Holdings (RANI) Cash from Financing Activities (2020 - 2026)

Rani Therapeutics Holdings has reported Cash from Financing Activities for 7 years, with the latest figure at $18.8 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 9903.19% year-over-year to $18.8 million in Q2 2026; TTM through Jun 2026 was $62.6 million, a 540.31% increase from a year earlier, with the FY2025 full-year figure at $40.3 million, up 196.65% from the prior year.
• Cash from Financing Activities was $18.8 million for Q2 2026 at Rani Therapeutics Holdings, up from -$27000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $44.9 million in Q4 2025, with the low at -$3.7 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is $6.0 million, with a median of $121000.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 15622.45% in 2024, then plunged 3183.47% in 2025.
• Over 5 years, Cash from Financing Activities stood at $14.9 million in 2022, then sank by 99.35% to $96000.0 in 2023, then jumped by 5753.12% to $5.6 million in 2024, then surged by 698.22% to $44.9 million in 2025, then plunged by 58.07% to $18.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $18.8 million (Q2 2026), -$27000.0 (Q1 2026), and $44.9 million (Q4 2025), per Business Quant data.